It took the US Food & Drug Administration (FDA) 12 years after launching a safety review of the allergy-and-asthma drug Singulair before it required a black-box warning about serious neuropsychiatric side effects, including suicidal thinking, in 2020. Responding to decades of escalating concerns about the commonly prescribed drug, it deployed one of its most potent tools: a … Continue reading FDA inaction despite asthma drug link to suicide